AntriaBio Inc Share Price OTC Bulletin Board
Equities
US0372301095
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-17 | Transcript : Rezolute, Inc. - Shareholder/Analyst Call | |
04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | 23.49M 1.85B | Capitalization | 106M 8.34B |
---|---|---|---|---|---|
Net income 2024 * | -63M -4.96B | Net income 2025 * | -54M -4.25B | EV / Sales 2024 * | - |
Net cash position 2024 * | 86M 6.77B | Net cash position 2025 * | 68M 5.35B | EV / Sales 2025 * | 1.62 x |
P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-3.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.62% |
Latest transcript on AntriaBio Inc
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 25/07/10 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 25/07/10 |
Daron Evans
DFI | Director of Finance/CFO | 50 | 01-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 25/07/10 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 09/02/19 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 19/11/19 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |